Telephone
61.2.9256.2505
Address
Level 23 180 George Street Salesforce Tower Sydney, New South Wales (NSW) 2000
Description
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.28 - 0.61
Trade Value (12mth)
AU$19,518.00
1 week
-6.35%
1 month
0%
YTD
-39.22%
1 year
-49.94%
All time high
1.84
EPS 3 yr Growth
15.80%
EBITDA Margin
N/A
Operating Cashflow
-$13m
Free Cash Flow Return
0.00%
ROIC
0.00%
Interest Coverage
-25.60
Quick Ratio
0.30
Shares on Issue (Fully Dilluted)
231m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.06
Date | Announcements |
---|---|
17 June 25 |
Recce Signs Debt Facility with Avenue Capital Group
×
Recce Signs Debt Facility with Avenue Capital Group |
17 June 25 |
Proposed issue of securities - RCE
×
Proposed issue of securities - RCE |
12 June 25 |
Change in substantial holding
×
Change in substantial holding |
11 June 25 |
Change in substantial holding
×
Change in substantial holding |
10 June 25 |
Application for quotation of securities - RCE
×
Application for quotation of securities - RCE |
10 June 25 |
Cleansing Notice
×
Cleansing Notice |
06 June 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
03 June 25 |
Successful Placement of Entitlement Offer Shortfall
×
Successful Placement of Entitlement Offer Shortfall |
26 May 25 |
China Patent Accepted for RECCE Anti-Infectives
×
China Patent Accepted for RECCE Anti-Infectives |
20 May 25 |
Change in substantial holding
×
Change in substantial holding |
16 May 25 |
Application for quotation of securities - RCE
×
Application for quotation of securities - RCE |
16 May 25 |
Results of Entitlement Offer
×
Results of Entitlement Offer |
16 May 25 |
Change of Director's Interest Notices
×
Change of Director's Interest Notices |
05 May 25 |
Canadian R&D Rebate Received
×
Canadian R&D Rebate Received |
30 April 25 |
Extension of Entitlement Offer Closing Date
×
Extension of Entitlement Offer Closing Date |
30 April 25 |
Update - Proposed issue of securities - RCE
×
Update - Proposed issue of securities - RCE |
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 April 25 |
Recce Enters into USA Department of Defense R&D Agreement
×
Recce Enters into USA Department of Defense R&D Agreement |
23 April 25 |
Investor Webinar Recording Available
×
Investor Webinar Recording Available |
23 April 25 |
Ceasing to be a substantial holder from MQG
×
Ceasing to be a substantial holder from MQG |
22 April 25 |
Phase II Clinical Trial Receives Additional Approval for DFI
×
Phase II Clinical Trial Receives Additional Approval for DFI |
22 April 25 |
Entitlement Offer - Offer Booklet and Access Letter
×
Entitlement Offer - Offer Booklet and Access Letter |
22 April 25 |
Entitlement Offer - Notification to Ineligible Shareholders
×
Entitlement Offer - Notification to Ineligible Shareholders |
17 April 25 |
Application for quotation of securities - RCE
×
Application for quotation of securities - RCE |
17 April 25 |
Placement Settlement Completed
×
Placement Settlement Completed |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.